[Oncocytic tumours of the kidney-new differential diagnoses].
Onkozytäre Tumoren der Niere – neue Differenzialdiagnosen.
Chromophobe renal cell carcinoma
ESC
MTOR
Oncocytoma
SDH
Journal
Der Pathologe
ISSN: 1432-1963
Titre abrégé: Pathologe
Pays: Germany
ID NLM: 8006541
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
accepted:
14
07
2021
pubmed:
2
9
2021
medline:
27
10
2021
entrez:
1
9
2021
Statut:
ppublish
Résumé
Recent developments in differential diagnosis have led to new knowledge about oncocytic renal neoplasms. Overview of differential diagnosis of oncocytic tumours. We performed a literature search on oncocytic renal tumours and mapped known tumour types. Possible differential diagnoses are discussed. Besides the tumour types already acknowledged by the 2016 WHO classification, there is new evidence regarding the group of hard-to-classify oncocytic neoplasms. Findings point to immunohistochemical and molecular characteristics that may lead to the establishment of new entities in the future. In addition, important differential diagnosis can now be identified, facilitating specific therapies for oncocytic renal tumours. A correct diagnosis of oncocytic renal tumours not only improves prognostic assessment (and, if necessary, specific therapies) but is also clinically relevant regarding a possible association with hereditary tumour syndromes. HINTERGRUND: Das Spektrum der onkozytären Tumoren der Niere hat sich durch neue Erkenntnisse erweitert. Erstellung einer Übersicht zur Differenzialdiagnose onkozytärer Tumoren der Niere. Eine Literaturrecherche zu onkozytären Tumoren der Niere wurde durchgeführt und die etablierten Entitäten werden dargestellt. Mögliche Differenzialdiagnosen werden diskutiert. Neben den bereits anerkannten Entitäten der World Health Organisation (WHO) 2016 gibt es neue Erkenntnisse in der Gruppe der bisher nicht eindeutig klassifizierbaren onkozytären Nierentumoren, bei denen sich Charakteristika in Immunhistochemie und auf molekularer Ebene abzeichnen, die zukünftig eine Etablierung neuer Entitäten anbahnen. Wichtige Differenzialdiagnosen können zudem abgegrenzt werden, was eine spezifische Therapie onkozytärer Nierentumoren ermöglicht. Die korrekte Diagnose onkozytärer Nierentumoren ermöglicht nicht nur eine verbesserte Prognoseeinschätzung (und ggf. spezifische Therapieoptionen), sondern ist auch im Hinblick auf eine mögliche Assoziation zu einem Tumordispositionssyndrom klinisch von Bedeutung.
Sections du résumé
BACKGROUND
BACKGROUND
Recent developments in differential diagnosis have led to new knowledge about oncocytic renal neoplasms.
OBJECTIVES
OBJECTIVE
Overview of differential diagnosis of oncocytic tumours.
MATERIALS AND METHODS
METHODS
We performed a literature search on oncocytic renal tumours and mapped known tumour types. Possible differential diagnoses are discussed.
RESULTS
RESULTS
Besides the tumour types already acknowledged by the 2016 WHO classification, there is new evidence regarding the group of hard-to-classify oncocytic neoplasms. Findings point to immunohistochemical and molecular characteristics that may lead to the establishment of new entities in the future. In addition, important differential diagnosis can now be identified, facilitating specific therapies for oncocytic renal tumours.
CONCLUSION
CONCLUSIONS
A correct diagnosis of oncocytic renal tumours not only improves prognostic assessment (and, if necessary, specific therapies) but is also clinically relevant regarding a possible association with hereditary tumour syndromes.
ZUSAMMENFASSUNG
UNASSIGNED
HINTERGRUND: Das Spektrum der onkozytären Tumoren der Niere hat sich durch neue Erkenntnisse erweitert.
FRAGESTELLUNG
UNASSIGNED
Erstellung einer Übersicht zur Differenzialdiagnose onkozytärer Tumoren der Niere.
MATERIAL UND METHODEN
METHODS
Eine Literaturrecherche zu onkozytären Tumoren der Niere wurde durchgeführt und die etablierten Entitäten werden dargestellt. Mögliche Differenzialdiagnosen werden diskutiert.
ERGEBNISSE
UNASSIGNED
Neben den bereits anerkannten Entitäten der World Health Organisation (WHO) 2016 gibt es neue Erkenntnisse in der Gruppe der bisher nicht eindeutig klassifizierbaren onkozytären Nierentumoren, bei denen sich Charakteristika in Immunhistochemie und auf molekularer Ebene abzeichnen, die zukünftig eine Etablierung neuer Entitäten anbahnen. Wichtige Differenzialdiagnosen können zudem abgegrenzt werden, was eine spezifische Therapie onkozytärer Nierentumoren ermöglicht.
SCHLUSSFOLGERUNG
UNASSIGNED
Die korrekte Diagnose onkozytärer Nierentumoren ermöglicht nicht nur eine verbesserte Prognoseeinschätzung (und ggf. spezifische Therapieoptionen), sondern ist auch im Hinblick auf eine mögliche Assoziation zu einem Tumordispositionssyndrom klinisch von Bedeutung.
Autres résumés
Type: Publisher
(ger)
HINTERGRUND: Das Spektrum der onkozytären Tumoren der Niere hat sich durch neue Erkenntnisse erweitert.
Identifiants
pubmed: 34468818
doi: 10.1007/s00292-021-00979-w
pii: 10.1007/s00292-021-00979-w
doi:
Types de publication
Journal Article
Review
Langues
ger
Sous-ensembles de citation
IM
Pagination
551-559Informations de copyright
© 2021. Springer Medizin Verlag GmbH, ein Teil von Springer Nature.
Références
Agaimy A (2016) Succinate dehydrogenase (SDH)-deficient renal cell carcinoma. Pathologe 37:144–152
pubmed: 26979428
pmcid: 26979428
Amin M, Tikoo SK (2016) Diagnostic pathology, 2. Aufl. Genitourinary, S 243
Argani P, Aulmann S, Karanjawala Z et al (2009) Melanotic Xp11 translocation renal cancers: a distinctive neoplasm with overlapping features of PEComa, carcinoma, and melanoma. Am J Surg Pathol 33:609–619
pubmed: 19065101
pmcid: 19065101
Bardella C, El-Bahrawy M, Frizzell N et al (2011) Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status. J Pathol 225:4–11
pubmed: 21630274
pmcid: 21630274
Bian L, Duan J, Wang X et al (2019) Sarcomatoid chromophobe renal cell carcinoma: a case report and review of the literature. Am J Case Rep 20:1225–1230
pubmed: 31423007
pmcid: 31423007
Bruder E, Moch H (2016) Das Translokationskarzinom. Pathologe 37:159–165
pubmed: 26972595
pmcid: 26972595
Chen YB, Brannon AR, Toubaji A et al (2014) Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry. Am J Surg Pathol 38:627–637
pubmed: 24441663
pmcid: 24441663
Chen YB, Mirsadraei L, Jayakumaran G et al (2019) Somatic mutations of TSC2 or MTOR characterize a morphologically distinct subset of sporadic renal cell carcinoma with eosinophilic and vacuolated cytoplasm. Am J Surg Pathol 43:121–131
pubmed: 30303819
pmcid: 30303819
Cheville JC, Lohse CM, Sukov WR et al (2012) Chromophobe renal cell carcinoma: the impact of tumor grade on outcome. Am J Surg Pathol 36:851–856
pubmed: 22367296
pmcid: 22367296
Davis CF, Ricketts CJ, Wang M et al (2014) The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell 26:319–330
pubmed: 25155756
pmcid: 25155756
Delahunt B, Cheville JC, Martignoni G et al (2013) The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol 37:1490–1504
pubmed: 24025520
pmcid: 24025520
Erlmeier F, Agaimy A, Hartmann A et al (2019) Pathologie und Molekularpathologie des Nierenzellkarzinoms. Onkologe 25:497–511
Gill AJ, Hes O, Papathomas T et al (2014) Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients. Am J Surg Pathol 38:1588–1602
pubmed: 25025441
pmcid: 4229399
Gill AJ, Pachter NS, Chou A et al (2011) Renal tumors associated with germline SDHB mutation show distinctive morphology. Am J Surg Pathol 35:1578–1585
pubmed: 21934479
pmcid: 21934479
Guo Q, Liu N, Wang F et al (2021) Characterization of a distinct low-grade oncocytic renal tumor (CD117-negative and cytokeratin 7‑positive) based on a tertiary oncology center experience: the new evidence from China. Virchows Arch 478:449–458
pubmed: 32918598
pmcid: 32918598
He H, Trpkov K, Martinek P et al (2018) “High-grade oncocytic renal tumor”: morphologic, immunohistochemical, and molecular genetic study of 14 cases. Virchows Arch 473:725–738
pubmed: 30232607
pmcid: 30232607
He W, Cheville JC, Sadow PM et al (2013) Epithelioid angiomyolipoma of the kidney: pathological features and clinical outcome in a series of consecutively resected tumors. Mod Pathol 26:1355–1364
pubmed: 23599151
pmcid: 23599151
Kufer V, Schwab SA, Büttner M et al (2012) Incidental monotypic (fat-poor) renal angiomyolipoma diagnosed by core needle biopsy. Case Rep Med 2012:906924
pubmed: 22548082
pmcid: 22548082
Lehtonen HJ (2011) Hereditary leiomyomatosis and renal cell cancer: update on clinical and molecular characteristics. Fam Cancer 10:397–411
pubmed: 21404119
pmcid: 21404119
Li Y, Reuter VE, Matoso A et al (2018) Re-evaluation of 33 ‘unclassified’ eosinophilic renal cell carcinomas in young patients. Histopathology 72:588–600
pubmed: 28898443
pmcid: 28898443
Liu L, Qian J, Singh H et al (2007) Immunohistochemical analysis of chromophobe renal cell carcinoma, renal oncocytoma, and clear cell carcinoma: an optimal and practical panel for differential diagnosis. Arch Pathol Lab Med 131:1290–1297
pubmed: 17683191
pmcid: 17683191
Martignoni G, Pea M, Bonetti F et al (2002) Oncocytoma-like angiomyolipoma. A clinicopathologic and immunohistochemical study of 2 cases. Arch Pathol Lab Med 126:610–612
pubmed: 11958671
pmcid: 11958671
Martignoni G, Pea M, Bonetti F et al (1998) Carcinomalike monotypic epithelioid angiomyolipoma in patients without evidence of tuberous sclerosis: a clinicopathologic and genetic study. Am J Surg Pathol 22:663–672
pubmed: 9630173
pmcid: 9630173
Merino MJ, Torres-Cabala C, Pinto P et al (2007) The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Am J Surg Pathol 31:1578–1585
pubmed: 17895761
pmcid: 17895761
Michalova K, Tretiakova M, Pivovarcikova K et al (2020) Expanding the morphologic spectrum of chromophobe renal cell carcinoma: A study of 8 cases with papillary architecture. Ann Diagn Pathol 44:151448
pubmed: 31918172
pmcid: 31918172
Mikami S, Kuroda N, Nagashima Y et al (2019) Classification of solid renal tumor with oncocytic/eosinophilic cytoplasm: is hybrid oncocytic/chromophobe renal tumor a subtype of oncocytoma, chromophobe renal cell carcinoma, or a distinct tumor entity? Ann Transl Med 7:S350
pubmed: 32016068
pmcid: 32016068
Moch H, Cubilla AL, Humphrey PA et al (2016) The 2016 WHO classification of tumours of the urinary system and Male genital organs—Part A: renal, penile, and testicular tumours. Eur Urol 70:93–105
pubmed: 26935559
pmcid: 26935559
Moch H, Ohashi R (2021) Chromophobe renal cell carcinoma: current and controversial issues. Pathology 53:101–108
pubmed: 33183792
pmcid: 33183792
Muller M, Guillaud-Bataille M, Salleron J et al (2018) Pattern multiplicity and fumarate hydratase (FH)/S-(2-succino)-cysteine (2SC) staining but not eosinophilic nucleoli with perinucleolar halos differentiate hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinomas from kidney tumors without FH gene alteration. Mod Pathol 31:974–983
pubmed: 29410489
pmcid: 29410489
Nese N, Martignoni G, Fletcher CD et al (2011) Pure epithelioid PEComas (so-called epithelioid angiomyolipoma) of the kidney: a clinicopathologic study of 41 cases: detailed assessment of morphology and risk stratification. Am J Surg Pathol 35:161–176
pubmed: 21263237
pmcid: 21263237
Ohashi R (2021) stains vimentin. https://www.pathologyoutlines.com/topic/stainsvimentin.html . Zugegriffen: 19. Mai 2021
Ohashi R, Angori S, Batavia AA et al (2020) Loss of CDKN1A mRNA and protein expression are independent predictors of poor outcome in chromophobe renal cell carcinoma patients. Cancers. https://doi.org/10.3390/cancers12020465
doi: 10.3390/cancers12020465
pubmed: 33374707
pmcid: 33374707
Ohashi R, Martignoni G, Hartmann A et al (2020) Multi-institutional re-evaluation of prognostic factors in chromophobe renal cell carcinoma: proposal of a novel two-tiered grading scheme. Virchows Arch 476:409–418
pubmed: 31760491
pmcid: 31760491
Ohashi R, Schraml P, Angori S et al (2019) Classic chromophobe renal cell carcinoma incur a larger number of chromosomal losses than seen in the eosinophilic subtype. Cancers. https://doi.org/10.3390/cancers11101492
doi: 10.3390/cancers11101492
pubmed: 31623347
pmcid: 6826417
Ohashi R, Schraml P, Batavia A et al (2019) Allele loss and reduced expression of CYCLOPS genes is a characteristic feature of chromophobe renal cell carcinoma. Transl Oncol 12:1131–1137
pubmed: 31200327
pmcid: 6563336
Perrino CM, Grignon DJ, Williamson SR et al (2018) Morphological spectrum of renal cell carcinoma, unclassified: an analysis of 136 cases. Histopathology 72:305–319
pubmed: 28833389
Petersson F, Gatalica Z, Grossmann P et al (2010) Sporadic hybrid oncocytic/chromophobe tumor of the kidney: a clinicopathologic, histomorphologic, immunohistochemical, ultrastructural, and molecular cytogenetic study of 14 cases. Virchows Arch 456:355–365
pubmed: 20300772
Reuter VE, Argani P, Zhou M et al (2014) Best practices recommendations in the application of immunohistochemistry in the kidney tumors: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol 38:e35–e49
pubmed: 25025368
Ruiz-Cordero R, Rao P, Li L et al (2019) Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma. Mod Pathol 32:1698–1707
pubmed: 31231128
Rupp NJ, Moch H (2020) Charakterisierung der unterschiedlichen Entitäten beim Nierenzellkarzinom. Urologe 59:135–141
Siadat F, Trpkov K (2020) ESC, ALK, HOT and LOT: three letter acronyms of emerging renal entities knocking on the door of the WHO classification. Cancers. https://doi.org/10.3390/cancers12010168
doi: 10.3390/cancers12010168
pubmed: 31936678
pmcid: 31936678
Skala SL, Wang X, Zhang Y et al (2020) Next-generation RNA sequencing-based Biomarker characterization of chromophobe renal cell carcinoma and related oncocytic neoplasms. Eur Urol 78:63–74
pubmed: 32299640
pmcid: 32299640
Smith SC, Sirohi D, Ohe C et al (2017) A distinctive, low-grade oncocytic fumarate hydratase-deficient renal cell carcinoma, morphologically reminiscent of succinate dehydrogenase-deficient renal cell carcinoma. Histopathology 71:42–52
pubmed: 28165631
pmcid: 28165631
Srigley JR, Delahunt B, Eble JN et al (2013) The International Society of Urological Pathology (ISUP) vancouver classification of renal neoplasia. Am J Surg Pathol 37:1469–1489
pubmed: 24025519
pmcid: 24025519
Störkel S, Eble JN, Adlakha K et al (1997) Classification of renal cell carcinoma. Cancer 80:987–989
pubmed: 9307203
pmcid: 9307203
Tickoo SK, Lee MW, Eble JN et al (2000) Ultrastructural observations on mitochondria and microvesicles in renal oncocytoma, chromophobe renal cell carcinoma, and eosinophilic variant of conventional (clear cell) renal cell carcinoma. Am J Surg Pathol 24:1247–1256
pubmed: 10976699
pmcid: 10976699
Tjota M, Chen H, Parilla M et al (2020) Eosinophilic renal cell tumors with a TSC and MTOR gene mutations are morphologically and Immunohistochemically heterogenous: clinicopathologic and molecular study. Am J Surg Pathol 44:943–954
pubmed: 32091432
pmcid: 32091432
Tjota MY, Wanjari P, Segal J et al (2020) TSC/MTOR mutated eosinophilic renal tumors are a distinct entity that are CK7+/CK20−/vimentin−: a validation study. Hum Pathol. https://doi.org/10.1016/j.humpath.2020.12.006
doi: 10.1016/j.humpath.2020.12.006
pubmed: 33352195
pmcid: 33352195
Trpkov K, Abou-Ouf H, Hes O et al (2017) Eosinophilic Solid and Cystic Renal Cell Carcinoma (ESC RCC): further morphologic and molecular characterization of ESC RCC as a distinct entity. Am J Surg Pathol 41:1299–1308
pubmed: 28786877
pmcid: 28786877
Trpkov K, Bonert M, Gao Y et al (2019) High-grade oncocytic tumour (HOT) of kidney in a patient with tuberous sclerosis complex. Histopathology 75:440–442
pubmed: 31002177
pmcid: 31002177
Trpkov K, Hes O, Williamson SR et al (2021) New developments in existing WHO entities and evolving molecular concepts: the Genitourinary Pathology Society (GUPS) update on renal neoplasia. Mod Pathol. https://doi.org/10.1038/s41379-021-00779-w
doi: 10.1038/s41379-021-00779-w
pubmed: 34611304
pmcid: 34611304
Trpkov K, Williamson SR, Gao Y et al (2019) Low-grade oncocytic tumour of kidney (CD117-negative, cytokeratin 7‑positive): a distinct entity? Histopathology 75:174–184
pubmed: 30895640
pmcid: 30895640
Trpkov K, Williamson SR, Gill AJ et al (2021) Novel, emerging and provisional renal entities: the Genitourinary Pathology Society (GUPS) update on renal neoplasia. Mod Pathol. https://doi.org/10.1038/s41379-021-00737-6
doi: 10.1038/s41379-021-00737-6
pubmed: 34611304
pmcid: 34611304
Trpkov K, Yilmaz A, Uzer D et al (2010) Renal oncocytoma revisited: a clinicopathological study of 109 cases with emphasis on problematic diagnostic features. Histopathology 57:893–906
pubmed: 21166703
pmcid: 21166703
Volpe A, Novara G, Antonelli A et al (2012) Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series. BJU Int 110:76–83
pubmed: 22044519
pmcid: 22044519